Molecular Cytogenetic Study of Immunofluorescently Labeled Plasma Cells and Prognostic Significance of Clonal Chromosomal Aberrations in Multiple Myeloma.
Rattachement africain : cz. Niveau de preuve : code pays fourni par la source.
Le résumé fourni par la source
Abstract Finding of clonal chromosomal aberrations in plasma cells is considered as one of the most important and independent prognostic factor in patients with multiple myeloma (MM). The most frequent and reliable cytogenetic indicators are chromosome 13q deletions (intermediate or moderately adverse prognosis), and translocations involving the immunoglobulin heavy chain gene (IgH) at 14q32 region. IgH gene is involved in translocations with different partner genes and these rearrangements are related to a very poor prognosis. The only exception is translocation t(11;14)(q13;q32) which is often connected with longer overall survival and therefore considered to be a favorable prognostic factor. The aim of the study was to assess the frequency of the most important chromosomal aberrations in immunofluorescently labeled plasma cells of patients with MM by interphase fluorescence in situ hybridization (I-FISH), and to evaluate their prognostic significance. During the last two years we examined 128 newly diagnosed patients with MM by conventional G-banding technique and by I-FISH. We focused on detection of aberrations of 13q, IgH gene rearrangements, and t(11;14)(q13;q32) translocation. I-FISH was done by locus-specific DNA probes (Abbott-Vysis, Des Plaines, Illinois, USA). Fifteen patients with complex karyotype were re-examined by multicolor FISH (mFISH, MetaSystems GmbH, Altlussheim, Germany). G-banding revealed abnormal karyotypes in 25% of patients, I-FISH detected chromosomal abberations in 82.8% cases. Abberations of chromosome 13 were found in plasma cells of 84 patients (65,6%), the incidence was: del(13)(q14) in 11%, monosomy 13 in 40%, combination of del(13)(q14)/monosomy 13 in 8%, and other aberrations of chromosome 13 in 7% of cases. Aberrations of IgH gene were proved in 82 patients (64%). t(11;14)(q13;q32) was seen in fourteen patients (11%) and other translocations affecting 14q32 region in 19 patients (15%). Besides translocations, different variations of total and/or partial deletions of IgH gene were detected in 28 cases (22%). In nine patients (7%) we found clones with translocation and deletion of 14q32 simultaneously, twelve patients (9%) had other IgH aberrations. Univariate statistical testing showed aberrations of 13q (p=0.042), and IgH gene rearrangments (translocations except t(11;14)(q13;q32) or deletions; p=0.007) to be associated with significantly shorter progression-free survival. The worst prognosis in our cohort was for 18 patients with combination of chromosome 13 anomalies together with rearrangements of IgH gene (p=0.049). Method of immunofluorescent labeling of plasma cells allows higher detection of chromosomal changes by I-FISH technique and therefore correct prognosis of the disease can be done.
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.
- Titre Crossref
- Molecular Cytogenetic Study of Immunofluorescently Labeled Plasma Cells and Prognostic Significance of Clonal Chromosomal Aberrations in Multiple Myeloma.
- Date Crossref
- 16/11/2006
- Éditeur
- American Society of Hematology
- Type
- journal-article
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.
Où se fait cette recherche
-
Charles University Institute of Clinical Biochemistry and Laboratory Diagnostics pays non établi dans la noticeUniversité ou école supérieure
-
Institute of Haematology and Blood Transfusion pays non établi dans la noticeStructure de recherche
-
University Hospital Kralovske Vinohrady pays non établi dans la noticeÉtablissement de santé
-
AeskuLab (Czechia) pays non établi dans la noticeEntreprise
-
Krajská Nemocnice Liberec pays non établi dans la noticeÉtablissement de santé
-
(Intr. by Jaroslav Cermak) pays non établi dans la noticeInstitution
-
Istitute of Hematology and Blood Transfusion pays non établi dans la noticeInstitution
-
Faculty Hospital Kralovske Vinohrady Dept. of Clinical Hematology pays non établi dans la noticeUniversité ou école supérieure
-
KLINLAB (Intr. by Jaroslav Cermak) pays non établi dans la noticeStructure de recherche
-
Klaudian Hospital Dept. of Hematology and Transfusion pays non établi dans la noticeÉtablissement de santé
-
Dept. of Clinical Hematology (Intr. by Jaroslav Cermak) pays non établi dans la noticeÉtablissement de santé
Institute of Clinical Biochemistry and Laboratory Diagnostics — Charles University, Institute of Haematology and Blood Transfusion et University Hospital Kralovske Vinohrady, avec 8 autres affiliations.
Une affiliation ne permet pas de déduire la nationalité d’un auteur.